A5055205639- Cell Adhesion Molecules Research
- Acute Myocardial Infarction Research
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Angiogenesis and VEGF in Cancer
- Ferroptosis and cancer prognosis
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Phagocytosis and Immune Regulation
- Sepsis Diagnosis and Treatment
- Frailty in Older Adults
- Nanoparticle-Based Drug Delivery
- Signaling Pathways in Disease
- Radiomics and Machine Learning in Medical Imaging
- Heart Failure Treatment and Management
- Immune cells in cancer
- Glycosylation and Glycoproteins Research
- Lung Cancer Research Studies
Oncode Institute
2023
Leiden University Medical Center
2023
Abstract Immune checkpoint blockade (ICB) has become the standard of care for several solid tumors. Multiple combinatorial approaches have been studied to improve therapeutic efficacy. The combination antiangiogenic agents and ICB demonstrated efficacy in cancers. To mechanistic understanding synergies with these treatment modalities, we performed screens sera from long-term responding patients treated ipilimumab bevacizumab. We discovered a high-titer antibody response against EGF-like...
<p>Pre-treatment (Pre) and post-treatment (Post) MFGE8 antibody titers to Ipi-Bev therapy in melanoma patients</p>
<div>Abstract<p>Immune checkpoint blockade (ICB) has become the standard of care for several solid tumors. Multiple combinatorial approaches have been studied to improve therapeutic efficacy. The combination antiangiogenic agents and ICB demonstrated efficacy in cancers. To mechanistic understanding synergies with these treatment modalities, we performed screens sera from long-term responding patients treated ipilimumab bevacizumab. We discovered a high-titer antibody response...
<p>Longitudinal analysis of EDIL3 antibody response to Ipi-Bev treatment in metastatic melanoma patients.</p>
<p>Volcano plots for EDIL3, MFGE8 and CTNNB1, with each spot representing Kendall rank correlation dysfunction or exclusion across TCGA tumor types.</p>
<p>Pre-treatment (Pre) and post-treatment (Post) MFGE8 antibody titers to Ipi-Bev therapy in melanoma patients</p>
<p>Gene expression (TPM) data from the bulk RNA-seq analysis.</p>
<p>Supplementary Figure legends</p>
<p>Gene expression (TPM) data from the bulk RNA-seq analysis.</p>
<p>EDIL3 antibody response to Ipi-Bev therapy in metastatic melanoma patients.</p>
<p>Molecular validation data.</p>
<p>Molecular validation data.</p>
<div>Abstract<p>Immune checkpoint blockade (ICB) has become the standard of care for several solid tumors. Multiple combinatorial approaches have been studied to improve therapeutic efficacy. The combination antiangiogenic agents and ICB demonstrated efficacy in cancers. To mechanistic understanding synergies with these treatment modalities, we performed screens sera from long-term responding patients treated ipilimumab bevacizumab. We discovered a high-titer antibody response...
<p>EDIL3 antibody response to Ipi-Bev therapy in metastatic melanoma patients.</p>
<p>Volcano plots for EDIL3, MFGE8 and CTNNB1, with each spot representing Kendall rank correlation dysfunction or exclusion across TCGA tumor types.</p>
<p>Longitudinal analysis of EDIL3 antibody response to Ipi-Bev treatment in metastatic melanoma patients.</p>
<p>Supplementary Figure legends</p>